As XRP enters a historically weak month, conflicting signals from whale accumulation, ETF flows, and exchange deposits set the stage for a volatile February 2026. Analysts pinpoint key levels that will determine the token's near-term trajectory.
Canadian National CEO Tracy Robinson has delivered a stark assessment of the proposed Union Pacific-Norfolk Southern merger, stating the railroads have "a long way to go" to satisfy regulatory concerns. In CN's earnings call, she criticized the application for failing to address competitive harms and warned of impacts on shippers, setting the stage for a contentious review process.
President Donald Trump has nominated Kevin Warsh, a former Federal Reserve governor known for his hawkish views and nuanced stance on Bitcoin, to chair the central bank. The move sets the stage for a contentious Senate confirmation battle and could herald a significant shift in U.S. monetary policy.
President Donald Trump's nomination of Kevin Warsh to lead the Federal Reserve sets the stage for a potential pivot in U.S. monetary policy, placing a seasoned yet controversial figure with deep Wall Street ties at the helm.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.
President Donald Trump has nominated Kevin Warsh, a former Federal Reserve governor and critic of current monetary policy, to succeed Jerome Powell as Chair of the Federal Reserve, setting the stage for a potential shift in the central bank's direction.
Elon Musk is reportedly in early-stage talks to merge his flagship companies—SpaceX, Tesla, and xAI—into a single, trillion-dollar technology and infrastructure behemoth ahead of a potential SpaceX IPO, sources familiar with the matter indicate.
After a punishing period, AGNC Investment Corp. staged a remarkable comeback in 2025. With a 12% dividend yield and a more favorable macroeconomic backdrop, the mortgage REIT is attracting income investors. But is the momentum sustainable?
Align Technology is accelerating its expansion in Southeast Asia with new product launches and affordability programs, a strategic pivot as the company navigates competitive pressures and seeks to reignite investor confidence amid a challenging stock performance.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
Worldcoin (WLD) plunged 21% in a volatile session, yet derivatives data reveals a cohort of traders profited from the downturn. Despite the crash, on-chain metrics suggest holder accumulation is limiting sell-side pressure, setting the stage for potential consolidation.
Uber Technologies is aggressively expanding its autonomous vehicle ecosystem through new partnerships and its AV Labs division, even as a landmark New Jersey court decision threatens to upend its core gig-economy labor model, setting the stage for a pivotal clash between its future vision and present-day regulatory challenges.
Summit Therapeutics (SMMT) finds itself at a crossroads, with its stock down over 30% in the past year. Conflicting signals from valuation models paint a complex picture: is the biotech firm dramatically overvalued on traditional metrics, or deeply undervalued based on future cash flows?
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
Blue Owl Capital faces a wave of securities class actions alleging disclosure failures around liquidity and redemptions, casting a shadow over its robust alternative asset management platform. As legal pressures mount, the market weighs solid analyst backing against growing governance concerns, setting the stage for a pivotal earnings report.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
